Literature DB >> 12200391

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

Rodrigo Martino1, María Dolores Caballero, José Antonio Pérez-Simón, José Antonio Pérez Simón, Carmen Canals, Carlos Solano, Alvaro Urbano-Ispízua, Joan Bargay, Angel Léon, Josep Sarrá, Guillermo F Sanz, José María Moraleda, Salut Brunet, Jesús San Miguel, Jorge Sierra.   

Abstract

We report the results of a prospective study of a reduced-intensity conditioning (RIC) regimen followed by allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA-identical sibling in 37 patients with acute myeloid leukemia (AML; n = 17) or myelodysplastic syndrome (MDS; n = 20). The median age was 57 years, and 22 (59%) were beyond the early phase of their disease. The incidence of grade II to IV acute graft-versus-host disease (GVHD) was 19% (5% grade III-IV), and the 1-year incidence of chronic extensive GVHD was 46%. With a median follow-up of 297 days (355 days in 24 survivors), the 1-year probability of transplant-related mortality was 5%, and the 1-year progression-free survival was 66%. The 1-year incidence of disease progression in patients with and without GVHD was 13% (95% CI, 4%-34%) and 58% (95% CI, 36%-96%), respectively (P =.008). These results suggest that a graft-versus-leukemia effect plays a crucial role in reducing the risk of relapse after a RIC allograft in AML and MDS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200391     DOI: 10.1182/blood-2002-02-0400

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  NKT cells, Treg, and their interactions in bone marrow transplantation.

Authors:  Holbrook E Kohrt; Asha B Pillai; Robert Lowsky; Samuel Strober
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

Review 2.  Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies.

Authors:  Michael J Ricci; Jeffrey A Medin; Ronan S Foley
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

Review 3.  Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.

Authors:  Aravind Ramakrishnan; Brenda M Sandmaier
Journal:  Expert Rev Hematol       Date:  2010-02-01       Impact factor: 2.929

Review 4.  Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?

Authors:  Mark A Schroeder; William Blum
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

Review 5.  Chronic graft-versus-host disease: Pathogenesis and clinical management.

Authors:  José A Pérez-Simón; Ignacio Sánchez-Abarca; María Díez-Campelo; Dolores Caballero; Jesús San Miguel
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Comparison of 2 preparative regimens for stem cell transplantation from HLA-matched sibling donors in patients with advanced myelodysplastic syndrome.

Authors:  Yoo-Jin Kim; Dong-Wook Kim; Seok Lee; Chang-Ki Min; Dong-Gun Lee; Soo-Mi Choi; Ki-Seong Eom; Hee-Je Kim; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

7.  Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.

Authors:  J M Li; Y Shen; D P Wu; H Liang; J Jin; F Y Chen; Y P Song; E Y P Song; X F Qiu; M Hou; Z C Qiu; Z X Shen
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

8.  Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.

Authors:  Hugo Castro-Malaspina; Ann A Jabubowski; Esperanza B Papadopoulos; Farid Boulad; James W Young; Nancy A Kernan; Miguel A Perales; Trudy N Small; Katharine Hsu; Michelle Chiu; Glenn Heller; Nancy H Collins; Suresh C Jhanwar; Marcel van den Brink; Stephen D Nimer; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

9.  Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence.

Authors:  Sylvain Perruche; Aliette Marandin; François Kleinclauss; Régis Angonin; Stéphanie Fresnay; Marie Hélène Baron; Pierre Tiberghien; Philippe Saas
Journal:  Transplantation       Date:  2006-02-27       Impact factor: 4.939

10.  Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

Authors:  Ginna G Laport; Brenda M Sandmaier; Barry E Storer; Bart L Scott; Monic J Stuart; Thoralf Lange; Michael B Maris; Edward D Agura; Thomas R Chauncey; Ruby M Wong; Stephen J Forman; Finn B Petersen; James C Wade; Elliot Epner; Benedetto Bruno; Wolfgang A Bethge; Peter T Curtin; David G Maloney; Karl G Blume; Rainer F Storb
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.